|
US20030176437A1
(en)
|
2001-08-31 |
2003-09-18 |
D.M. Watterson |
Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
|
|
DE102004010207A1
(de)
|
2004-03-02 |
2005-09-15 |
Aventis Pharma S.A. |
Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
|
|
DE102004010194A1
(de)
*
|
2004-03-02 |
2005-10-13 |
Aventis Pharma Deutschland Gmbh |
4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
|
|
EP1598348A1
(en)
|
2004-05-18 |
2005-11-23 |
Aventis Pharma Deutschland GmbH |
Novel pyridazinone derivatives as inhibitors of CDK2
|
|
EP1604988A1
(en)
|
2004-05-18 |
2005-12-14 |
Sanofi-Aventis Deutschland GmbH |
Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
|
|
US7951805B2
(en)
|
2004-09-20 |
2011-05-31 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
|
|
US7767677B2
(en)
|
2004-09-20 |
2010-08-03 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
|
|
EP1799667B1
(en)
|
2004-09-20 |
2013-03-20 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as therapeutic agents
|
|
EP2316458A1
(en)
|
2004-09-20 |
2011-05-04 |
Xenon Pharmaceuticals Inc. |
Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
|
|
CA2580856A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
|
EP1804799B1
(en)
|
2004-09-20 |
2013-08-21 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
|
EP2289510A1
(en)
|
2004-09-20 |
2011-03-02 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
|
|
ATE523199T1
(de)
|
2004-11-02 |
2011-09-15 |
Univ Northwestern |
Pyridazinverbindungen und verfahren
|
|
BRPI0517947A
(pt)
|
2004-11-02 |
2008-10-21 |
Univ Northwestern |
composto de piridazina, composições e métodos
|
|
EP2029138A1
(en)
|
2005-06-03 |
2009-03-04 |
Xenon Pharmaceuticals Inc. |
Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
|
|
EP2258357A3
(en)
|
2005-08-26 |
2011-04-06 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
EP2275096A3
(en)
|
2005-08-26 |
2011-07-13 |
Braincells, Inc. |
Neurogenesis via modulation of the muscarinic receptors
|
|
WO2007047978A2
(en)
|
2005-10-21 |
2007-04-26 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
|
EP2314289A1
(en)
|
2005-10-31 |
2011-04-27 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
JP2009535344A
(ja)
|
2006-04-28 |
2009-10-01 |
ノースウェスタン ユニバーシティ |
神経炎症性疾患の処置のためのピリダジン化合物を含む処方物
|
|
WO2007127475A2
(en)
*
|
2006-04-28 |
2007-11-08 |
Northwestern University |
Pyridazines for demyelinating diseases and neuropathic pain
|
|
CA2650711A1
(en)
|
2006-04-28 |
2007-11-08 |
Northwestern University |
Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
|
|
EP2021000A2
(en)
|
2006-05-09 |
2009-02-11 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
JP2010500300A
(ja)
|
2006-08-08 |
2010-01-07 |
サノフィ−アベンティス |
アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
CN101538245B
(zh)
|
2008-03-18 |
2011-02-16 |
中国科学院上海药物研究所 |
一类哒嗪酮类化合物及其制备方法和制备药物的用途
|
|
US9212146B2
(en)
|
2008-03-18 |
2015-12-15 |
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences |
Substituted pyridazinones for the treatment of tumors
|
|
WO2010003624A2
(en)
|
2008-07-09 |
2010-01-14 |
Sanofi-Aventis |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
|
US20100216805A1
(en)
|
2009-02-25 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
AU2012203023C1
(en)
*
|
2009-03-02 |
2013-11-07 |
Novartis Ag |
N-(hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as Wnt signaling modulators
|
|
UA103918C2
(en)
|
2009-03-02 |
2013-12-10 |
Айерем Элелси |
N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
|
|
SG178880A1
(en)
|
2009-08-26 |
2012-04-27 |
Sanofi Sa |
Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
UY33469A
(es)
*
|
2010-06-29 |
2012-01-31 |
Irm Llc Y Novartis Ag |
Composiciones y metodos para modular la via de señalizacion de wnt
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
EP2683698B1
(de)
|
2011-03-08 |
2017-10-04 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US8846666B2
(en)
|
2011-03-08 |
2014-09-30 |
Sanofi |
Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
|
EP2683704B1
(de)
|
2011-03-08 |
2014-12-17 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2683703B1
(de)
|
2011-03-08 |
2015-05-27 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US8809324B2
(en)
|
2011-03-08 |
2014-08-19 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
|
WO2012120055A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2766349B1
(de)
|
2011-03-08 |
2016-06-01 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
WO2012120054A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
WO2012120056A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
GB201201100D0
(en)
*
|
2012-01-20 |
2012-03-07 |
Medical Res Council |
Polypeptides and methods
|
|
EP3290407B1
(en)
|
2013-10-18 |
2020-01-01 |
Celgene Quanticel Research, Inc |
Bromodomain inhibitors
|
|
DK3107899T3
(da)
*
|
2014-02-19 |
2020-11-16 |
Aviv Therapeutics Inc |
Mitokondriel aldehyddehydrogenase 2 (aldh2)-bindende polycykliske amider og anvendelse deraf til cancerbehandling
|
|
SG11201810366WA
(en)
*
|
2016-05-25 |
2018-12-28 |
Bayer Pharma AG |
3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
|
|
US12522594B2
(en)
|
2017-02-09 |
2026-01-13 |
Deutsches Krebsforschungszentrum |
2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
|
|
WO2019101642A1
(en)
*
|
2017-11-21 |
2019-05-31 |
Bayer Aktiengesellschaft |
Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
|
|
BR112021002207A2
(pt)
|
2018-08-10 |
2021-05-04 |
Diapin Therapeutics, Llc |
tri-peptídeos e tratamento de distúrbios metabólicos, cardiovasculares e inflamatórios
|
|
CN111533697B
(zh)
*
|
2020-05-07 |
2023-03-31 |
成都大学 |
4-氨基哒嗪酮类化合物及其制备方法
|
|
CN111393374A
(zh)
*
|
2020-05-08 |
2020-07-10 |
张建蒙 |
氧代二氢哒嗪类衍生物及其在抗肿瘤药物中的应用
|
|
CN111533735A
(zh)
*
|
2020-05-08 |
2020-08-14 |
张建蒙 |
氧代二氢哒嗪噻唑类衍生物及其在抗肿瘤药物中的应用
|
|
WO2022113003A1
(en)
|
2020-11-27 |
2022-06-02 |
Rhizen Pharmaceuticals Ag |
Cdk inhibitors
|
|
WO2022149057A1
(en)
|
2021-01-05 |
2022-07-14 |
Rhizen Pharmaceuticals Ag |
Cdk inhibitors
|
|
CA3217792A1
(en)
|
2021-05-07 |
2022-11-10 |
Kymera Therapeutics, Inc |
Cdk2 degraders and uses thereof
|